Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Review
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate
Crimini Edoardoa Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;b Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy;c Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
https://orcid.org/0000-0002-1869-0607View further author information
https://orcid.org/0000-0002-1869-0607View further author information & Curigliano Giuseppea Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;b Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, ItalyCorrespondence[email protected]
https://orcid.org/0000-0003-1781-2518View further author information
https://orcid.org/0000-0003-1781-2518View further author information